Ionis Signs an Exclusive WW License Agreement with Bicycle to Develop Targeted Oligonucleotide Therapeutics Using TfR1 Bicycle Technology
Shots: Bicycle receives $45M as up front and is eligible to receive development, regulatory and commercial milestones along with royalties for each program developed under […]